Drug Profile
Research programme: inhaled therapeutics - Alexza Pharmaceuticals
Alternative Names: AZ-008; Ropinirole inhalation - AlexzaLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Alexza Pharmaceuticals
- Class Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Restless legs syndrome
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Restless legs syndrome in USA (Inhalation) (Alexza Pharmaceuticals pipeline, February 2023)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Restless legs syndrome in USA (Inhalation)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA (Inhalation, Aerosol)